SCHEMBL19781592

SCHEMBL19781592

COc1ccc(-n2cnc3ccc(-c4cccc(OC)c4)cc32)cc1

nearest known ligand 0.67

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.67
ALDH1A1 P00352 2/20 0.67
HPGD P15428 1/20 0.67
MAPK1 P28482 1/20 0.67
MAPK10 P53779 1/20 0.67
NCOA1 Q15788 1/20 0.67
NCOA3 Q9Y6Q9 1/20 0.67
KDR P35968 1/20 0.61
FGFR1 P11362 4/20 0.59
ATM Q13315 6/20 0.59
GSK3B P49841 3/20 0.58
MAPT P10636 1/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
CDK1 P06493 1/20 0.50
PRKCQ Q04759 1/20 0.50
MAP3K1 Q13233 1/20 0.50
GRM1 Q13255 1/20 0.50
HCAR1 Q9BXC0 1/20 0.47
SRC P12931 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18609552 0.91 KDR (0.74) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL19781279 0.90 KDR (0.68) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL18584814 0.87 ATM (0.55) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL16158542 0.87 FGFR1 (0.75) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL19781277 0.87 HTT (0.56) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL19781516 0.84 GSK3B (0.61) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL18584365 0.84 KDR (0.61) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL18584485 0.83 HTT (0.58) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL19781770 0.83 HTT (0.52) HTTALDH1A1HPGDMAPK1MAPK10
SCHEMBL19781278 0.82 KDR (0.58) HTTALDH1A1HPGDMAPK1MAPK10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193038-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2022-06-23 US disclosed
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus ARISAN THERAPEUTICS INC. (US) 2022-06-07 US disclosed
WO-2020117794-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS, INC. (US) 2020-06-11 WO disclosed
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2019-10-10 US disclosed
WO-2018013430-A2 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION ARISAN THERAPEUTICS INC. (US) 2018-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220193038-A1 COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION HAVCR2, ZC3HAV1, CD4 HTT 4815/4885ALDH1A1 1293/4885HPGD 2481/4885
US-11352328-B2 Heterocyclic compounds for the treatment of arenavirus C9, C1R, C1S HTT 1337/4885ALDH1A1 1146/4885HPGD 1350/4885
US-20190308938-A1 Heterocyclic Compounds for the Treatment of Arenavirus C9, C1R, C1S HTT 1337/4885ALDH1A1 1146/4885HPGD 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.